<DOC>
	<DOC>NCT00386061</DOC>
	<brief_summary>The primary objective was to assess the effect of SR141716 on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with or without comorbidities. The main secondary objectives were to assess the effect of SR141716 on lipid parameters (HDL-C, TG), glucose tolerance status, the rate of patients with metabolic syndrome, waist circumference, glycemic parameters.</brief_summary>
	<brief_title>Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>body mass index (BMI) e30 kg/m2 in patients with or without comorbidities, or BMI &gt;27 kg/m2 in patients with treated or untreated hypertension and/or treated or untreated dyslipidemia. stable body weight (variation &lt;5 kg within 3 months prior to screening visit); History of very lowcalorie diet within 6 months prior to screening visit; or history of surgical procedures for body weight loss (eg, stomach stapling, bypass); Presence of any clinically significant psychiatric , neurological or endocrine disease Presence of treated or untreated type 1 or type 2 diabetes); SBP &gt;165 mmHg and/or DBP &gt;105 mmHg on 2 consecutive visits from the screening to the inclusion visit; History of myocardial infarction or unstable angina pectoris within 6 months prior to screening visit; and history of stroke within 6 months prior to screening visit; Administration of antiobesity drugs or other drugs for body weight reduction within 3 months prior to screening visit; The investigator will evaluate whether there are other reasons why a patient may not participate.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Obesity</keyword>
	<keyword>risk factors</keyword>
</DOC>